Abstract: Objective To observe the clinical efficacy of Tiggio（S-1），Oxaliplatin plus Apatinib as first-line treatment for patients with advanced gastric cancer. Methods Eighty-eight patients with advanced gastric cancer who were admitted to the Xinjiang Uygur Autonomous Region people's Hospital from February 2015 to October 2016 were enrolled. They were randomly divided into the control group （44 cases） and the experimental group （44 cases）. The control group was given S-1  combined with oxaliplatin chemotherapy（SOX），while the experimental group was given SOX plus Apatinib. Short-term efficacy，adverse reactions，overall survival and progression-free survival of the two groups were compared. Results The objective remission rate in the experimental group was significantly higher than that in the control group （40.91% vs 20.45%，χ²=4.238，P=0.037）. There was no significant difference in disease control rate between the two groups （86.36% vs 70.45%，χ²=3.289，P=0.070）. The median over survival of the experimental group was signicantly longer than that of the control group（12 months vs 9.5 months，χ²=4.254，P=0.039）. The median progression-free survival was also significantly longer than that of the control group （9 months vs 6 months，χ²=8.815，P=0.003）. The total incidence of hypertension and hand-foot syndrome in the experimental group was higher than that in the control group（P<0.05），and the incidence of other adverse reactions was not statistically significant（P＞0.05）. Conclusion SOX plus Apatinib as first-line treatment for advanced gastric cancer patients has demonstrated good clinical efficacy. It is safe and can effectively prolong the survival time and disease free progression time .

Key words: Gastric neoplasms, Tiggio, Oxaliplatin, Apatinib, Efficacy, Safety